

Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

Acetaminophen Safety in Cirrhosis

Jonathan A. Dranoff, MD

Director, Fatty Liver Program
VA Connecticut Healthcare System, West Haven, CT

Mitchell R. McGill, PhD

Assistant Professor, Department of Pharmacology and Toxicology, University of
Arkansas for Medical Sciences, Little Rock, AR

Tuesday, January 25, 2022

5:00 pm - 6:00 pm

<https://zoom.us/j/98990743210?pwd=a1BkVXJvNVdqR0ZyT0o4aVNqMzFrUT09>

Moderator: Joseph Lim, MD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29432) to 203-442-9435.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** At present, the options for effective treatment of pain in patients with cirrhosis are limited. Specifically, nonsteroidal anti-inflammatory drugs and opioids are dangerous in this population. Although there is ample evidence that acetaminophen is a cause of acute liver failure, the safety of acetaminophen in patients with cirrhosis is unknown. Thus, the need that will be addressed is an assessment of the safety of acetaminophen in patients with cirrhosis. **Objectives:** Understand considerations of study design when attempting to test drug safety in cirrhosis. Clarify the changes in drug metabolism observed in patients with cirrhosis. Clarify the changes in markers of liver injury observed in patients with cirrhosis. **Faculty Disclosures:** None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**